参考文献/References:
[1]Popma JJ,Deeb GM,Yakubov SJ,et al. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients[J]. N Engl J Med,2019,380(18):1706-1715.
[2]Nishimura RA,Otto CM,Bonow RO,et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease:a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines[J]. J Am Coll Cardiol,2017,70(2):252-289.
[3]吴永健. 经导管主动脉瓣置换术的现状、研究热点和未来展望 [J]. 中国循环杂志,2017,32(2):120-122.
[4]周达新,潘文志,吴永健,等. 经导管主动脉瓣置换术中国专家共识（2020更新版）[J].中国介入心脏病学杂志,2020,28(6):301-309.
[5]中华医学会心血管病学分会结构性心脏病学组,中国医师协会心血管内科医师分会结构性心脏病专业委员会. 中国经导管主动脉瓣置换术临床路径专家共识[J]. 中国循环杂志,2018,33(12):1162-1169.
[6]Baumgartner H,Falk V,Bax JJ,et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease[J]. Eur Heart J,2017,38(36):2739-2791.
[7]Vahanian A,Beyersdorf F,Praz F,et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease[J].Eur Heart J,2022,43(7):561-632.
[8]Reardon MJ,van Mieghem NM,Popma JJ,et al. Surgical or transcatheter aortic-valve replacement in intermediate-risk patients[J]. N Engl J Med,2017,376(14):1321-1331.
[9]Leon MB,Smith CR,Mack M,et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery[J]. N Engl J Med,2010,363(1):1597-1607.
[10]Smith CR,Leon MB,Mack MJ,et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients[J]. N Engl J Med,2011,364(23):2187-2198.
[11]Mack MJ,Leon MB,Thourani VH,et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients[J]. N Engl J Med,2019,380(18):1695-1705.
[12]Grover FL,Vemulapalli S,Carroll JD,et al. 2016 Annual report of the Society of Thoracic Surgeons/American College of Cardiology transcatheter valve therapy registry[J]. J Am Coll Cardiol,2017,69(10):1215-1230.
[13]Dangas GD,Tijssen JGP,W?hrle J,et al.A controlled trial of rivaroxaban after transcatheter aortic-valve replacement[J]. N Engl J Med,2020,382(2):120-129.
[14] Nijenhuis VJ,Brouwer J,Delewi R,et al. Anticoagulation with or without clopidogrel after transcatheter aortic-valve implantation[J]. N Engl J Med,2020,382(18):1696-1707.
[15] Brouwer J,Nijenhuis VJ,Delewi R,et al. Aspirin with or without clopidogrel after transcatheter aortic-valve implantation[J]. N Engl J Med ,2020,383(15):1447-1457.
[16]Hassell ME,Hildick-Smith D,Durand E,et al. Antiplatelet therapy following transcatheter aortic valve implantation[J]. Heart,2015,101(14):1118-1125.
[17]Mangieri A,Jabbour RJ,Montalto C,et al. Single-antiplatelet therapy in patients with contraindication to dual-antiplatelet therapy after transcatheter aortic valve implantation[J]. Am J Cardiol,2017,119(7):1088-1093.
[18]Ichibori Y,Mizote I,Maeda K,et al. Clinical outcomes and bioprosthetic valve function after transcatheter aortic valve implantation under dual antiplatelet therapy vs. aspirin alone[J]. Circ J,2017,81(3):397-404.
[19]Rodés-Cabau J,Masson JB,Welsh RC,et al. Aspirin versus aspirin plus clopidogrel as antithrombotic treatment following transcatheter aortic valve replacement with a balloon-expandable valve:the ARTE(Aspirin Versus Aspirin?+ Clopidogrel Following?Transcatheter Aortic Valve Implantation) randomized clinical trial[J]. JACC Cardiovasc Interv,2017,10(13):1357-1365.
[20]Ten Berg J,Sibbing D,Rocca B,et al. Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation:a consensus document of the ESC Working Group on Thrombosis and the European Association of Percutaneous Cardiovascular Interventions(EAPCI),in collaboration with the ESC Council on Valvular Heart Disease[J]. Eur Heart J,2021,42(23):2265-2269.
[21]Hindricks G,Potpara T,Dagres N,et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery(EACTS):the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology(ESC) developed with the special contribution of the European Heart Rhythm Association(EHRA) of the ESC[J]. Eur Heart J,2021,42(5):373-498.
[22]Seeger J,Gonska B,Rodewald C,et al. Apixaban in patients with atrial fibrillation after transfemoral aortic valve replacement[J]. JACC Cardiovasc Interv,2017,10(1):66-74.
[23]Butt JH,de Backer O,Olesen JB,et al. Vitamin K antagonists vs. direct oral anticoagulants after transcatheter aortic valve implantation in atrial fibrillation[J]. Eur Heart J Cardiovasc Pharmacother,2021,7(1):11-19.
[24]Jochheim D,Barbanti M,Capretti G,et al. Oral anticoagulant type and outcomes after transcatheter aortic valve replacement[J]. JACC Cardiovasc Interv,2019,12(16):1566-1576.
[25]Abdul-Jawad Altisent O,Durand E,Mu?oz-García AJ,et al. Warfarin and antiplatelet therapy versus warfarin alone for treating patients with atrial fibrillation undergoing transcatheter aortic valve replacement[J]. JACC Cardiovasc Interv,2016,9(16):1706-1717.
[26]Blanke P,Leipsic JA,Popma JJ,et al. Bioprosthetic aortic valve leaflet thickening in the Evolut low risk sub-study[J]. J Am Coll Cardiol,2020,75(19):2430-2442.
[27]de Backer O,Dangas GD,Jilaihawi H,et al. Reduced leaflet motion after transcatheter aortic-valve replacement[J]. N Engl J Med,2020,382(2):130-139.
[28]Makkar RR,Blanke P,Leipsic J,et al. Subclinical leaflet thrombosis in transcatheter and surgical bioprosthetic valves:PARTNER 3 cardiac computed tomography substudy[J]. J Am Coll Cardiol,2020,75(24):3003-3015.
[29]Rheude T,Pellegrini C,Stortecky S,et al. Meta-analysis of bioprosthetic valve thrombosis after transcatheter aortic valve implantation[J]. Am J Cardiol,2021,138:92-99.
[30]Sannino A,Hahn RT,Leipsic J,et al. Meta-analysis of incidence,predictors and consequences of clinical and subclinical bioprosthetic leaflet thrombosis after transcatheter aortic valve implantation[J]. Am J Cardiol,2020,132:106-113.
[31]Stachon P,Kaier K,Heidt T,et al. The use and outcomes of cerebral protection devices for patients undergoing transfemoral transcatheter?aortic valve replacement in clinical prac tice[J]. JACC Cardiovasc Interv,2021,14(2):161-168.
[32]Attinger-Toller A,Maisano F,Senn O,et al. “One-Stop Shop”:safety of combining transcatheter aortic valve replacement and left atrial appendage occlusion[J]. JACC Cardiovasc Interv,2016,9(14):1487-1495.
[33]Urena M,Rodés-Cabau J,Freixa X,et al.Percutaneous left atrial appendage closure with the AMPLATZER cardiac plug device in patients with nonvalvular atrial fibrillation and contraindications to anticoagulation therapy[J].J Am Coll Cardiol,2013,62(2):96-102.
[34]Reddy VY,Mobius-Winkler S,Miller MA,et al.Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation:the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology)[J].J Am Coll Cardiol,2013,61(25):2551-2556.
相似文献/References:
[1]于子凯 许海燕 刘庆荣 吴永健.合并常见疾病对经导管主动脉瓣置换术患者预后的影响[J].心血管病学进展,2019,(5):697.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.009]
YU Zikai,XU Haiyan,LIU Qingrong,et al.Influence of ommon Accompanied Diseases on Prognosis of Patients after Transcatheter Aortic Valve Replacement[J].Advances in Cardiovascular Diseases,2019,(7):697.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.009]
[2]王斯佳 王国兴.抗栓治疗后消化道出血的现状及抗栓策略[J].心血管病学进展,2020,(8):790.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.002]
WANG Sijia,WANG G uoxing.Current Characteristics and Anti-thrombotic Strategy of Gastrointestinal Hemorrhage after Anti-thrombotic Therapy[J].Advances in Cardiovascular Diseases,2020,(7):790.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.002]
[3]邵美华 周玉强 王萌萌 王宝珠 马翔.经导管主动脉瓣置换术治疗二叶式主动脉瓣狭窄研究进展[J].心血管病学进展,2020,(11):1184.[doi:10.16806/j.cnki.issn.1004-3934.2020.11.000]
[4]刘新民 宋光远 吴永健.左心室导丝起搏技术在经导管主动脉瓣置换术中的应用[J].心血管病学进展,2021,(4):289.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.001]
LIU Xinmin,SONG Guangyuan,WU Yongjian.Application of Left Ventricular Guidewire Pacing in Transcatheter Aortic Valve Replacement[J].Advances in Cardiovascular Diseases,2021,(7):289.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.001]
[5]陈阳 赵庆豪 赵杰 吴永健.经导管主动脉瓣置换术时代慢性主动脉瓣反流诊治进展[J].心血管病学进展,2022,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.001]
CHEN Yang,ZHAO Qinghao,SONG Guangyuan,et al.Diagnosis and Treatment of Chronic Aortic Regurgitation in Transcatheter Aortic Valve Replacement Era[J].Advances in Cardiovascular Diseases,2022,(7):1.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.001]
[6]索妮 杨艳敏.心房颤动合并慢性冠状动脉综合征的抗栓治疗进展[J].心血管病学进展,2022,(1):30.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.008]
SUO Ni,Y ANG Yanmin.Antithrombotic Therapy for Atrial Fibrillation Complicated with Chronic Coronary Syndrome[J].Advances in Cardiovascular Diseases,2022,(7):30.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.008]
[7]董一娜 雷芳芳 宋启煦 王晶 杨艳.经导管主动脉瓣置换术后死亡风险预测模型系统评价[J].心血管病学进展,2022,(1):76.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.020]
DONG Yina,LEI Fangfang,SONG Qixu,et al.Mortality Risk Prediction Models After Transcatheter?span>Aortic Valve Replacement:A Systematic Review[J].Advances in Cardiovascular Diseases,2022,(7):76.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.020]
[8]王卫卫 于子凯 吴永健 许海燕 刘庆荣.序贯综合心脏康复模式在经导管主动脉瓣置换术患者中应用现状[J].心血管病学进展,2022,(8):673.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.001]
WANG Weiwei,YU Zikai,WU YongjianXU HaiyanLIU Qingrong.The Status of Sequential Comprehensive Cardiac Rehabilitation in Patients?ndergoing Transcatheter Aortic Valve Replacement[J].Advances in Cardiovascular Diseases,2022,(7):673.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.001]
[9]张航 安景辉 石凤梧.极简式经导管主动脉瓣置换术的研究现状[J].心血管病学进展,2022,(9):812.[doi:10.16806/j.cnki.issn.1004-3934.2022.09.011]
ZHANG Hang,AN Jinghui,SHI Fengwu.Minimalist Transcatheter Aortic Valve Replacement[J].Advances in Cardiovascular Diseases,2022,(7):812.[doi:10.16806/j.cnki.issn.1004-3934.2022.09.011]
[10]金冉阳 刘德敏 崔炜.经皮冠状动脉介入治疗围手术期抗栓治疗的演变[J].心血管病学进展,2023,(1):39.[doi:10.16806/j.cnki.issn.1004-3934.2023.01.010]
JIN Ranyang,LIU Demin,CUI Wei.Evolution of Antithrombotic Therapy During Perioperative PCI[J].Advances in Cardiovascular Diseases,2023,(7):39.[doi:10.16806/j.cnki.issn.1004-3934.2023.01.010]
[11]李宗泽 何贵均 郑晓菲 蒋晖 刘汉雄.经导管主动脉瓣置换术后合并心房颤动的抗栓策略[J].心血管病学进展,2021,(10):892.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.007]
LI ZongzeHE GuijunZHENG XiaofeiJIANG HuiLIU Hanxiong.Optimal Antithrombotic Strategies after Transcatheter Aortic Valve Replacement in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2021,(7):892.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.007]
[12]张木馨 李丽英 阮海燕 何森.经导管主动脉瓣置换术后抗栓治疗进展[J].心血管病学进展,2022,(6):518.[doi:10.16806/j.cnki.issn.1004-3934.2022.06.010]
ZHANG Muxin,LI Liying,RUAN Haiyan,et al.Progress of Antithrombotic Therapy after?ranscatheter Aortic Valve Replacement[J].Advances in Cardiovascular Diseases,2022,(7):518.[doi:10.16806/j.cnki.issn.1004-3934.2022.06.010]